Edesa Biotech, Inc. — Director's Dealing 2019

Jun 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edesa Biotech, Inc. (EDSA)
CIK: 0001540159
Period of Report: 2019-06-07

Reporting Person: van der Velden Peter (Director, 10% Owner)
Reporting Person: Lumira Capital Investment Management Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-07	Common Shares	A	1611338	$0.00	Acquired	1611338	Indirect
2019-06-07	Common Shares	A	148999	$0.00	Acquired	148999	Indirect

Footnotes

F1: Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc.

F2: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ["LCII LP"], (ii) Lumira Capital II (International), L.P. ["LCII INT LP"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.

F3: All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019.